scholarly article | Q13442814 |
P50 | author | Peter G. Schultz | Q899840 |
P2093 | author name string | Eduardo Laborda | |
Travis S Young | |||
Ashley K Woods | |||
Xinxin Wang | |||
David T Rodgers | |||
Chan Hyuk Kim | |||
Herlinda Quirino | |||
Eric N Hampton | |||
Sida Shao | |||
Magdalena Mazagova | |||
P2860 | cites work | Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. | Q40135347 |
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia | Q40314122 | ||
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment | Q41873361 | ||
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer | Q42157682 | ||
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
Modulation of human neutrophil survival and antigen expression by activated CD4+ and CD8+ T cells. | Q45256536 | ||
Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways | Q77137106 | ||
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens | Q81663230 | ||
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia | Q83030425 | ||
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. | Q34329186 | ||
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia | Q34368778 | ||
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells | Q34645694 | ||
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. | Q35146288 | ||
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia | Q35591409 | ||
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy | Q36328394 | ||
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. | Q36408432 | ||
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies | Q36551673 | ||
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. | Q37117781 | ||
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells | Q37244349 | ||
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. | Q37272020 | ||
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice | Q37554901 | ||
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells | Q37697847 | ||
Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia | Q38972314 | ||
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. | Q39026376 | ||
Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity | Q39026688 | ||
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies | Q39038206 | ||
Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. | Q39240280 | ||
Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia | Q39817951 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P577 | publication date | 2017-10-27 | |
P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
P1476 | title | Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia | |
P478 | volume | 18 |
Q90413936 | A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy |
Q100958764 | A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells |
Q55292778 | Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? |
Q103728286 | Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor |
Q64245424 | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
Q57898900 | Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML |
Q97538364 | Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia |
Q89805236 | Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond |
Q93017003 | Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML |
Q48091597 | Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. |
Q64094664 | Targeting CLL-1 for acute myeloid leukemia therapy |
Search more.